Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab
Related Posts
Wu C, Wang L, Wang N, Shiao S, Dou T, Hsu YC, Christodoulou AG, Xie Y, Li D. Prediction of Early Neoadjuvant Chemotherapy Response of[...]
Jin Z, Aa G, Guo Y, Liu H, Sun H, Li Z, Ma M, Fonarow G, Gao Y, Zhao D, Yang Q, Zhou X; CCC-AF[...]
Miyazaki Y, Rimmer M, Peacock WJ, Xu S, Shivkumar K, Mori S. Three-Dimensional Printing of the Human Pericardium to Facilitate Understanding of the Pericardial Reflections,[...]